---
layout: default
title: Treprostinil
description: "Treprostinil çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 184
evidence_level: L5
indication_count: 10
---

# Treprostinil

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Treprostinilï¼šå¾è‚ºå‹•è„ˆé«˜å£“åˆ°ç›¸é—œä½µç™¼ç—‡

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Treprostinil å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Treprostinil (å‹µè„ˆå±•ç´ ) åŸæœ¬ç”¨æ–¼æ²»ç™‚ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¤šç¨®è‚ºå‹•è„ˆé«˜å£“ç›¸é—œç–¾ç—…**æœ‰æ•ˆï¼Œ
å…¶ä¸­**çµç· çµ„ç¹”ç–¾ç—…ç›¸é—œè‚ºå‹•è„ˆé«˜å£“**æœ‰æœ€å¼·çš„è‡¨åºŠè­‰æ“šæ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ (WHO functional class III/IV) |
| é æ¸¬æ–°é©æ‡‰ç—‡ | pulmonary arteriovenous malformation (disease)ã€pulmonary arterial hypertensionã€pulmonary arterial hypertension associated with congenital heart diseaseã€pulmonary arterial hypertension associated with HIV infectionã€pulmonary arterial hypertension associated with chronic hemolytic anemiaã€pulmonary arterial hypertension associated with connective tissue diseaseã€pulmonary arterial hypertension associated with schistosomiasisã€hypotrichosis simplex of the scalpã€congenital hypotrichosis miliaã€malformation syndrome with odontal and/or periodontal component |
| TxGNN æœ€é«˜é æ¸¬åˆ†æ•¸ | 99.70% (è‚ºå‹•éœè„ˆç•¸å½¢) |
| è­‰æ“šç­‰ç´š | L2 (çµç· çµ„ç¹”ç–¾ç—…ç›¸é—œ PAH) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 25 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |

## é æ¸¬æ–°é©æ‡‰ç—‡ä¸€è¦½

| ç–¾ç—…åç¨± | TxGNN åˆ†æ•¸ | è‡¨åºŠè©¦é©— | æ–‡ç»æ•¸ |
|---------|-----------|---------|-------|
| è‚ºå‹•éœè„ˆç•¸å½¢ | 99.70% | 0 | 0 |
| å…ˆå¤©æ€§å¿ƒè‡Ÿç—…ç›¸é—œ PAH | 99.60% | 2 | 20+ |
| HIV æ„ŸæŸ“ç›¸é—œ PAH | 99.55% | 1 | 5 |
| çµç· çµ„ç¹”ç–¾ç—…ç›¸é—œ PAH | 99.55% | 2 | 20+ |
| æ…¢æ€§æº¶è¡€æ€§è²§è¡€ç›¸é—œ PAH | 99.55% | 0 | 0 |
| è¡€å¸èŸ²ç—…ç›¸é—œ PAH | 99.55% | 0 | 0 |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. pulmonary arteriovenous malformation (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.70%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Treprostinil æ˜¯ä¸€ç¨®å‰åˆ—ç’°ç´ é¡ä¼¼ç‰©ï¼Œå…¶ä½œç”¨æ©Ÿè½‰æ”¯æŒåœ¨å„é¡è‚ºå‹•è„ˆé«˜å£“ä¸­çš„æ‡‰ç”¨ï¼š

1. **è¡€ç®¡æ“´å¼µ**ï¼šç›´æ¥æ“´å¼µè‚ºè¡€ç®¡åŠå…¨èº«è¡€ç®¡
2. **æŠ—è¡€å°æ¿ä½œç”¨**ï¼šæŠ‘åˆ¶è¡€å°æ¿èšé›†
3. **æŠ—å¢æ®–ä½œç”¨**ï¼šæŠ‘åˆ¶è¡€ç®¡å¹³æ»‘è‚Œç´°èƒå¢æ®–
4. **ç´°èƒä¿è­·ä½œç”¨**ï¼šä¿è­·å…§çš®ç´°èƒåŠŸèƒ½

é€™äº›æ©Ÿè½‰é©ç”¨æ–¼å„ç¨®ç—…å› å°è‡´çš„è‚ºå‹•è„ˆé«˜å£“ï¼ŒåŒ…æ‹¬çµç· çµ„ç¹”ç–¾ç—…ã€å…ˆå¤©æ€§å¿ƒè‡Ÿç—…ã€HIV æ„ŸæŸ“ç­‰ã€‚

### è‡¨åºŠè©¦é©—

### çµç· çµ„ç¹”ç–¾ç—…ç›¸é—œ PAH
| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| ç›¸é—œè©¦é©— | Phase 2/3 | COMPLETED | N/A | Treprostinil å¯æ”¹å–„ CTD-PAH æ‚£è€…çš„é‹å‹•è€åŠ›åŠè¡€æµå‹•åŠ›å­¸åƒæ•¸ |

### å…ˆå¤©æ€§å¿ƒè‡Ÿç—…ç›¸é—œ PAH
| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| ç›¸é—œè©¦é©— | Phase 2 | COMPLETED | N/A | è©•ä¼° Treprostinil åœ¨è‰¾æ£®æ›¼æ ¼ç—‡å€™ç¾¤æ‚£è€…ä¸­çš„ç™‚æ•ˆ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [15302727](https://pubmed.ncbi.nlm.nih.gov/15302727/) | 2004 | RCT | Chest | Treprostinil çš®ä¸‹æ³¨å°„æ²»ç™‚ CTD-PAH çš„ç™‚æ•ˆèˆ‡å®‰å…¨æ€§ |
| [11897647](https://pubmed.ncbi.nlm.nih.gov/11897647/) | 2002 | RCT | Ann Intern Med | Treprostinil åœ¨è‚ºå‹•è„ˆé«˜å£“ä¸­çš„ç™‚æ•ˆ |
| [22621693](https://pubmed.ncbi.nlm.nih.gov/22621693/) | 2012 | Review | Drugs | CTD-APAH æ²»ç™‚æŒ‡å—å»ºè­°ä½¿ç”¨ Treprostinil (I-B æ¨è–¦) |
| [41594679](https://pubmed.ncbi.nlm.nih.gov/41594679/) | 2026 | Review | Biomolecules | è¨è«– CTD-PAH ç›®å‰æ²»ç™‚ç­–ç•¥åŠå¸å…¥å¼ Treprostinil çš„è§’è‰² |
| [22291467](https://pubmed.ncbi.nlm.nih.gov/22291467/) | 2012 | Review | Drug Des Devel Ther | å¸å…¥å¼ Treprostinil çš„è‡¨åºŠæ‡‰ç”¨å›é¡§ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. pulmonary arterial hypertension associated with congenital heart disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.60%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.60%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pulmonary arterial hypertension associated with HIV infection</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.55%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary arterial hypertension associated with chronic hemolytic anemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.55%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. pulmonary arterial hypertension associated with connective tissue disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.55%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. pulmonary arterial hypertension associated with schistosomiasis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.55%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hypotrichosis simplex of the scalp</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.48%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.48%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. congenital hypotrichosis milia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.30%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.30%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. malformation syndrome with odontal and/or periodontal component</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.21%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.21%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. Ambras type hypertrichosis universalis congenita</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.17%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.17%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨ç½•è—¥è¼¸å­—ç¬¬000071è™Ÿ | å‹µè„ˆå±•ç´ æ³¨å°„åŠ‘1æ¯«å…‹/æ¯«å‡ | æ³¨å°„åŠ‘ | ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ (WHO class III/IV) |
| è¡›éƒ¨ç½•è—¥è¼¸å­—ç¬¬000072è™Ÿ | å‹µè„ˆå±•ç´ æ³¨å°„åŠ‘2.5æ¯«å…‹/æ¯«å‡ | æ³¨å°„åŠ‘ | ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ (WHO class III/IV) |
| è¡›éƒ¨ç½•è—¥è¼¸å­—ç¬¬000074è™Ÿ | å‹µè„ˆå±•ç´ æ³¨å°„åŠ‘10æ¯«å…‹/æ¯«å‡ | æ³¨å°„åŠ‘ | ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ (WHO class III/IV) |
| è¡›éƒ¨ç½•è—¥è¼¸å­—ç¬¬000096è™Ÿ | æ³°è‚ºèˆ’å£è…”å¸å…¥æ¶² | å£è…”å¸å…¥åŠ‘ | ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ (NYHA class III) |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬029038è™Ÿ | æ‹“è‚ºé¬†å£è…”å¸å…¥æ¶² | å£è…”å¸å…¥åŠ‘ | é–“è³ªæ€§è‚ºç—…é€ æˆçš„è‚ºé«˜å£“ |

## å®‰å…¨æ€§è€ƒé‡

- **çµ¦è—¥é€”å¾‘**ï¼šçš®ä¸‹æ³¨å°„å¯èƒ½å¼•èµ·æ³¨å°„éƒ¨ä½ç–¼ç—›åŠåæ‡‰
- **è¡€å£“å½±éŸ¿**ï¼šå¯èƒ½å¼•èµ·ä½è¡€å£“
- **å‡ºè¡€é¢¨éšª**ï¼šæŠ—è¡€å°æ¿ä½œç”¨å¯èƒ½å¢åŠ å‡ºè¡€é¢¨éšª
- **ä¸»è¦äº¤äº’ä½œç”¨ (Moderate)**ï¼š
  - Acetylsalicylic acidï¼ˆå¢åŠ å‡ºè¡€é¢¨éšªï¼‰
  - SGLT2 æŠ‘åˆ¶åŠ‘ï¼ˆCanagliflozinã€Dapagliflozinã€Empagliflozinï¼‰
  - Epinephrineï¼ˆå¯èƒ½å½±éŸ¿è¡€å£“èª¿ç¯€ï¼‰


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Hemorrhage** ğŸŸ¡ Moderate
- Treprostinil injection inhibits platelet aggregation and increases the risk of bleeding.  Close monitoring is recommended when using this agent in patients with bleeding disorders.

**Diverticulum** ğŸŸ¡ Moderate
- The tablet shell of the manufactured form of treprostinil, Orenitram does not dissolve and can lodge in the diverticulum of patients with diverticulosis.  Care should be exercised when using this drug in patient with diverticulosis.

**ä½è¡€å£“ (Hypotension)** ğŸŸ¡ Moderate
- Treprostinil is a pulmonary and systemic vasodilator.  In patients with low systemic arterial pressure, treatment with treprostinil injection may produce symptomatic hypotension.  Care should be exercised when using this agent in patients at risk.

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Severe hepatic impairment (Child Pugh Class C) is a contraindication in patients taking the oral presentation of treprostinil.  Treprostinil is substantially metabolized by the liver, primarily by CYP450 2C8.  Treprostinil injection clearance is redu...

**Pneumonia** ğŸŸ¡ Moderate
- The efficacy of treprostinil inhalant has not been established in patients with significant underlying lung disease.  Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effe...

*å¦æœ‰ 2 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Treprostinil åœ¨çµç· çµ„ç¹”ç–¾ç—…ç›¸é—œè‚ºå‹•è„ˆé«˜å£“ä¸­å·²æœ‰å……åˆ†çš„è‡¨åºŠè­‰æ“šæ”¯æŒï¼Œæ­æ´²æ²»ç™‚æŒ‡å—å·²å°‡å…¶åˆ—ç‚º I-B ç­‰ç´šæ¨è–¦ã€‚å°æ–¼å…¶ä»–é æ¸¬çš„é©æ‡‰ç—‡ï¼ˆå¦‚å…ˆå¤©æ€§å¿ƒè‡Ÿç—…ç›¸é—œ PAHï¼‰ï¼Œä¹Ÿæœ‰è‡¨åºŠè©¦é©—å’Œæ–‡ç»æ”¯æŒã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é‡å°ç‰¹å®šäºå‹ï¼ˆå¦‚ HIV ç›¸é—œ PAHï¼‰çš„é€²ä¸€æ­¥ç ”ç©¶
- å¸å…¥å¼åŠ‘å‹åœ¨ä¸åŒ PAH äºå‹ä¸­çš„ç™‚æ•ˆè©•ä¼°
- èˆ‡å…¶ä»– PAH æ²»ç™‚è—¥ç‰©çš„æ¯”è¼ƒç ”ç©¶


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Povidone]({{ "/drugs/povidone/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Irbesartan]({{ "/drugs/irbesartan/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cytarabine]({{ "/drugs/cytarabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Atezolizumab]({{ "/drugs/atezolizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Remdesivir]({{ "/drugs/remdesivir/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Treprostinilè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/treprostinil/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_treprostinil,
  title = {Treprostinilè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/treprostinil/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
